Fig. 1

Characterization of patient-derived xenograft models. (a) Representative H&E and immunostainings of the original patients' tumors and the corresponding patient-derived xenograft models (passage used in the in vivo experiment). (b) PDGFRA immunostainings of control tumors of the different patient-derived xenograft models. 200x: 200-fold magnification; 400x: 400-fold magnification; α-SMA: alpha smooth muscle actin; H&E: hematoxylin and eosin; PDGFRA: platelet-derived growth factor receptor alpha; *: necrotic area in the UZLX-STS59 model